Real-world outcomes of first-line immunotherapy and subsequent systemic therapies in pleural mesothelioma: a multicenter study in China
Binhe Tian, Boyu Sun, Zixiang Zhou, Shuman Kuang, Jiongyuan Li, Weixuan Pan, Zhe Zhu, Xiaoyan Si, Li Zhang, Jun Liu, Juhong Shi, Fang Wu, Haitao Zhao, Hanping Wang · 2025
Read Real-world outcomes of first-line immunotherapy and subsequent systemic therapies in pleural mesothelioma: a multicenter study in China by Binhe Tian, Boyu Sun, Zixiang Zhou, Shuman Kuang, Jiongyuan Li, Weixuan Pan, Zhe Zhu, Xiaoyan Si, Li Zhang, Jun Liu, Juhong Shi, Fang Wu, Haitao Zhao, Hanping Wang (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12775688.txt.
Description
Binhe Tian and co-authors compared first treatments for pleural mesothelioma, a cancer of the lung lining, using real hospital records from across China, in a study published in 2025. Immune drugs have reshaped first-line care for this poor-outlook cancer, yet everyday evidence from Chinese patients was thin.
Seventy-eight patients treated between 2015 and 2025 were split into those who began with immune therapy and those who began with chemotherapy, with or without targeted drugs. After statistical balancing, the immune-first group lived longer, with a hazard about half that of the other group. Time without the disease worsening also trended longer. The study further compares what worked after the first treatment failed, a choice clinics face with little guidance.
Catalog record
| CREATOR | Binhe Tian, Boyu Sun, Zixiang Zhou, Shuman Kuang, Jiongyuan Li, Weixuan Pan, Zhe Zhu, Xiaoyan Si, Li Zhang, Jun Liu, Juhong Shi, Fang Wu, Haitao Zhao, Hanping Wang |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 36 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |